Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Brian, Woodfall"'
Autor:
Sandra De Meyer, Denisa Bojkova, Jindrich Cinatl, Ellen Van Damme, Christophe Buyck, Marnix Van Loock, Brian Woodfall, Sandra Ciesek
Publikováno v:
International Journal of Infectious Diseases, Vol 97, Iss , Pp 7-10 (2020)
Objectives: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors a
Externí odkaz:
https://doaj.org/article/90d3b12b6ba74d96bc31c99b569501e3
Autor:
Kati Vandermeulen, Thomas N. Kakuda, Monika Peeters, Tine De Marez, Richard M. W. Hoetelmans, Brian Woodfall, Fatima Aharchi
Publikováno v:
Journal of Antimicrobial Chemotherapy. 69:728-734
Objectives: Drug– drug interactions between etravirine and rifabutin or clarithromycin were examined in two separate open-label, randomized, two-period, crossover trials in HIV-negative, healthy volunteers. Methods: Rifabutin study: 16 participants
Autor:
Johan Vingerhoets, Bonaventura Clotet, Steven Nijs, Jean-Michel Molina, Richard Haubrich, William J. Towner, Brian Woodfall, James Witek, Anthony Mills, Beatriz Grinsztejn, Benoit Trottier, Christine Katlama
Publikováno v:
Antiviral Therapy. 15:1045-1052
Background Durable efficacy and long-term safety of antiretroviral therapy are important goals in the management of treatment-experienced patients. The 96-week efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) etraviri
Autor:
Benoit Trottier, Johan Vingerhoets, Monika Peeters, Giovanni Di Perri, José Valdez Madruga, Brian Woodfall, Gaston Picchio
Publikováno v:
HIV Clinical Trials. 11:175-185
This subgroup analysis of the phase 3 DUET trials examined the impact of the background regimen on virologic response to etravirine in treatment-experienced patients.Patients received etravirine 200 mg or placebo, both twice daily with a background r
Autor:
Annemie Hoogstoel, Goedele De Smedt, Monika Peeters, Steven Nijs, Johan Vingerhoets, Marie-Pierre de Béthune, Hilde Azijn, Brian Woodfall, Gaston Picchio, Lotke Tambuyzer
Publikováno v:
AIDS. 24:503-514
Objective: To refine the genotypic and phenotypic correlates of response to the nonnucleoside reverse transcriptase inhibitor etravirine. Design: Initial analyses identified 13 etravirine resistance-associated mutations (RAMs) and clinical cutoffs (C
Autor:
Monika Peeters, Fatima Aharchi, Richard M. W. Hoetelmans, Thomas N. Kakuda, Brian Woodfall, Monika Schöller-Gyüre, Kati Vandermeulen
Publikováno v:
Contraception. 80:44-52
Background Etravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant HIV, is an inducer of CYP3A4 and an inhibitor of CYP2C9/19. Study Design The effect of etravirine on the pharmacokinetics and pharmacodynam
Autor:
Monika Schöller-Gyüre, Brian Woodfall, Katrien Janssen, Ruth Lachaert, Goedele De Smedt, Monika Peeters, Thomas N. Kakuda, Richard M. W. Hoetelmans
Publikováno v:
Annals of Pharmacotherapy. 42:757-765
Background: Etravirine (TMC125), a next-generation nonnucleoside reverse transcriptase inhibitor, has shown antiviral efficacy in 2 large Phase 3 trials. In vitro and in vivo studies have shown that etravirine is not associated with proarrhythmic pot
Autor:
Goedele De Smedt, Wim van den Brink, Hilde Vanaken, Richard M. W. Hoetelmans, Thomas N. Kakuda, Monika Schöller-Gyüre, Monika Peeters, Brian Woodfall, Kati Vandermeulen, Tanja Stevens
Publikováno v:
Journal of clinical pharmacology, 48(3), 322-329. Wiley-Blackwell
TMC125 is a nonnucleoside reverse transcriptase inhibitor (NNRTI) with potent in vitro activity against wild-type and NNRTI-resistant HIV-1. TMC125 is an inducer of CYP3A and an inhibitor of CYP2C. This trial evaluated the effect of TMC125 on the pha
Autor:
Adriano Lazzarin, Thomas Campbell, Bonaventura Clotet, Margaret Johnson, Christine Katlama, Arend Moll, William Towner, Benoit Trottier, Monika Peeters, Johan Vingerhoets, Goedele de Smedt, Benny Baeten, Greet Beets, Rekha Sinha, Brian Woodfall
Publikováno v:
The Lancet. 370:39-48
Autor:
Brian Woodfall, Vanitha Sekar, Goedele De Smedt, Richard M. W. Hoetelmans, Monika Schöller-Gyüre, Thomas N. Kakuda, Eric Lefebvre, Monika Peeters
Publikováno v:
Antiviral Therapy. 12:789-796
ObjectiveTo evaluate the pharmacokinetics of TMC125 (etravirine) and darunavir (DRV) with low-dose ritonavir (DRV/r).DesignOpen-label, randomized, two-way crossover Phase I trial.MethodsThirty-two HIV-negative volunteers were randomized 1:1 to two pa